Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 296

1.

Improved design and intranasal delivery of an M2e-based human influenza A vaccine.

De Filette M, Fiers W, Martens W, Birkett A, Ramne A, Löwenadler B, Lycke N, Jou WM, Saelens X.

Vaccine. 2006 Nov 10;24(44-46):6597-601. Epub 2006 Jun 12.

PMID:
16814430
2.

The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.

De Filette M, Ramne A, Birkett A, Lycke N, Löwenadler B, Min Jou W, Saelens X, Fiers W.

Vaccine. 2006 Jan 30;24(5):544-51. Epub 2005 Aug 31.

PMID:
16169634
3.

Universal influenza A vaccine: optimization of M2-based constructs.

De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W.

Virology. 2005 Jun 20;337(1):149-61.

4.

A "universal" human influenza A vaccine.

Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W.

Virus Res. 2004 Jul;103(1-2):173-6. Review.

PMID:
15163506
5.

CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.

Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, Löwenadler B, Fiers W, Saelens X, Lycke N.

Vaccine. 2008 Feb 26;26(9):1243-52. doi: 10.1016/j.vaccine.2007.12.027. Epub 2008 Jan 10.

PMID:
18243429
6.

Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.

De Filette M, Martens W, Smet A, Schotsaert M, Birkett A, Londoño-Arcila P, Fiers W, Saelens X.

Vaccine. 2008 Dec 2;26(51):6503-7. doi: 10.1016/j.vaccine.2008.09.038.

PMID:
18835315
7.

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.

Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, Umlauf S, Tussey L, Powell TJ.

Vaccine. 2008 Jan 10;26(2):201-14. Epub 2007 Nov 20.

PMID:
18063235
8.

An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.

Zhao G, Sun S, Du L, Xiao W, Ru Z, Kou Z, Guo Y, Yu H, Jiang S, Lone Y, Zheng BJ, Zhou Y.

Virol J. 2010 Jul 12;7:151. doi: 10.1186/1743-422X-7-151.

9.

Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.

Park KS, Seo YB, Lee JY, Im SJ, Seo SH, Song MS, Choi YK, Sung YC.

Vaccine. 2011 Jul 26;29(33):5481-7. doi: 10.1016/j.vaccine.2011.05.062. Epub 2011 Jun 12.

PMID:
21664216
10.

M2e-based universal influenza A vaccine.

Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X.

Vaccine. 2009 Oct 23;27(45):6280-3. doi: 10.1016/j.vaccine.2009.07.007. Review.

PMID:
19840661
12.

Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.

Ravin NV, Blokhina EA, Kuprianov VV, Stepanova LA, Shaldjan AA, Kovaleva AA, Tsybalova LM, Skryabin KG.

Vaccine. 2015 Jun 26;33(29):3392-7. doi: 10.1016/j.vaccine.2015.04.066. Epub 2015 Apr 29.

PMID:
25937448
13.

Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.

Wu F, Yuan XY, Huang WS, Chen YH.

Vaccine. 2009 Oct 9;27(43):6095-101. doi: 10.1016/j.vaccine.2008.11.037. Epub 2008 Dec 3.

PMID:
19056447
14.

Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.

Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.

Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10.

15.

A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.

Eliasson DG, Helgeby A, Schön K, Nygren C, El-Bakkouri K, Fiers W, Saelens X, Lövgren KB, Nyström I, Lycke NY.

Vaccine. 2011 May 23;29(23):3951-61. doi: 10.1016/j.vaccine.2011.03.090. Epub 2011 Apr 8.

PMID:
21481325
16.

Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein.

Ravin NV, Kotlyarov RY, Mardanova ES, Kuprianov VV, Migunov AI, Stepanova LA, Tsybalova LM, Kiselev OI, Skryabin KG.

Biochemistry (Mosc). 2012 Jan;77(1):33-40. doi: 10.1134/S000629791201004X.

PMID:
22339631
17.

Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.

Tsybalova LM, Stepanova LA, Kuprianov VV, Blokhina EA, Potapchuk MV, Korotkov AV, Gorshkov AN, Kasyanenko MA, Ravin NV, Kiselev OI.

Vaccine. 2015 Jun 26;33(29):3398-406. doi: 10.1016/j.vaccine.2015.04.073. Epub 2015 May 11.

PMID:
25976545
18.

Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.

Sui Z, Chen Q, Wu R, Zhang H, Zheng M, Wang H, Chen Z.

Arch Virol. 2010 Apr;155(4):535-44. doi: 10.1007/s00705-010-0621-4. Epub 2010 Feb 27.

PMID:
20195654
19.

Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza.

Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, Park SM, Cheon IS, Joo DH, Cho CH, Song MS, Seo SU, Byun YH, Park HJ, Poo H, Seong BL, Kim JO, Nguyen HH, Stadler K, Kim DW, Hong KJ, Czerkinsky C, Song MK.

PLoS One. 2011;6(11):e27953. doi: 10.1371/journal.pone.0027953. Epub 2011 Nov 30.

20.

Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e.

Li R, Lim A, Ow ST, Phoon MC, Locht C, Chow VT, Alonso S.

Vaccine. 2011 Jul 26;29(33):5502-11. doi: 10.1016/j.vaccine.2011.05.052. Epub 2011 May 30.

PMID:
21624415

Supplemental Content

Support Center